Clinical bottom line
Osteoporotic fragility fractures are a significant public health concern, particularly among the elderly population. Updated guidance emphasizes a multifaceted approach to prevention, incorporating lifestyle modifications, pharmacotherapy, and fall prevention strategies. Bisphosphonates remain the first-line pharmacological treatment, with newer agents such as denosumab and romosozumab offering additional options for patients at high risk of fracture. Individualized risk assessment and management plans are crucial for optimizing outcomes and minimizing fracture risk.
What the evidence shows
Recent guidelines and studies highlight the efficacy of bisphosphonates, such as alendronate and zoledronic acid, in reducing the risk of vertebral and non-vertebral fractures. A meta-analysis by Wells et al. (2018) confirmed that bisphosphonates significantly reduce fracture risk in postmenopausal women with osteoporosis [PMID: 29562059].
Denosumab, a monoclonal antibody that inhibits RANKL, has been shown to reduce vertebral, non-vertebral, and hip fractures in postmenopausal women with osteoporosis. The FREEDOM trial demonstrated a 68% reduction in vertebral fractures with denosumab compared to placebo [PMID: 19420363].
Romosozumab, a sclerostin inhibitor, has emerged as a novel treatment option. The ARCH trial found that romosozumab followed by alendronate significantly reduced the risk of vertebral and clinical fractures compared to alendronate alone [PMID: 28605718].
Lifestyle interventions, including adequate calcium and vitamin D intake, weight-bearing exercise, and smoking cessation, are essential components of fracture prevention. Fall prevention strategies, such as home safety assessments and balance training, are also critical, particularly for older adults.
Caveats and uncertainty
While bisphosphonates are effective, long-term use has been associated with rare adverse effects, such as atypical femoral fractures and osteonecrosis of the jaw. These risks necessitate periodic reevaluation of the need for continued therapy.
Denosumab discontinuation can lead to rapid bone loss and increased fracture risk, highlighting the importance of transition strategies to other therapies upon cessation. The long-term safety of newer agents like romosozumab requires further investigation, particularly concerning cardiovascular risk.
The variability in individual responses to treatment underscores the need for personalized approaches, considering factors such as baseline fracture risk, comorbid conditions, and patient preferences.
How this may change practice
The updated guidance on osteoporotic fragility fracture prevention supports a comprehensive, individualized approach to management. Clinicians should assess fracture risk using tools such as FRAX and consider both pharmacological and non-pharmacological strategies to reduce risk.
The introduction of newer agents like denosumab and romosozumab provides additional options for patients at high risk of fracture or those who cannot tolerate bisphosphonates. As evidence continues to evolve, treatment guidelines may further refine recommendations for the use of these agents.
Clinicians should remain informed about the latest research and guidelines to optimize patient outcomes and minimize fracture risk, emphasizing the importance of regular monitoring and reassessment of treatment plans.